By Michael Dabaie

 

Roche Holding AG's (RO.EB, ROG.EB) Genentech said data was positive from the Phase III IMpower110 study evaluating Tecentriq in advanced non-squamous and squamous non-small cell lung cancer.

Genentech said the study looked at Tecentriq as a monotherapy in advanced non-squamous and squamous non-small cell lung cancer without ALK or EGFR mutations.

The study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer with high PD-L1 expression live longer compared with chemotherapy alone, Genentech said.

The company said it will share the data with health authorities globally, including the U.S. Food and Drug Administration and European Medicines Agency.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

September 27, 2019 11:05 ET (15:05 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Roche (QX) Charts.